Drug intelligence / Profile preview

GKA23

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

GKA23 is a potent small molecule glucokinase activator, specifically the free alcohol derivative of AZD1656. It acts by activating glucokinase (GK), an enzyme that plays a central role in glucose sensing and regulation in pancreatic beta cells and the liver. By increasing GK activity, GKA23 enhances insulin secretion and promotes glucose uptake, thereby lowering blood glucose levels. Preclinical studies have shown that GKA23 induces insulin secretion even under euglycemic and hypoglycemic conditions[1][3][4]. The drug has been primarily investigated for its potential use in diabetes mellitus.

Targets

GCK (Glucokinase)

Beyond the preview

Go deeper on GKA23.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKA23.

Explore the full profile